Gp78 E3 ubiquitin ligase: Essential functions and contributions in proteostasis

Frontiers in Cellular Neuroscience

Volumn 11, Issue , 2017, Pages

  Joshi, Vibhuti ^a   Upadhyay, Arun ^a   Kumar, Amit ^b   Mishra, Amit ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY JODHPUR   (India)

^b INDIAN INSTITUTE OF TECHNOLOGY INDORE   (India)

Author keywords

Cancer; E3 ubiquitin ligases; Gp78; Neurodegenerative diseases; Neurons

Indexed keywords

CD82 ANTIGEN; COPPER ZINC SUPEROXIDE DISMUTASE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DIACYLGLYCEROL ACYLTRANSFERASE 2; GLYCOPROTEIN; GLYCOPROTEIN 78; HEAT SHOCK PROTEIN 70; HISTONE DEACETYLASE 6; INTERFERON; PEPTIDES AND PROTEINS; PHOSPHATIDYLINOSITOL 3 KINASE; RAM 1 HOMOLOG; STEROL REGULATORY ELEMENT BINDING PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

CELLULAR IMMUNITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION; ENDOPLASMIC RETICULUM STRESS; GENE OVEREXPRESSION; HUMAN; HUMAN ALPHAHERPESVIRUS 1; LIVER CELL CARCINOMA; MALIGNANT NEOPLASM; NERVE DEGENERATION; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN HOMEOSTASIS; PROTEIN INTERACTION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UBIQUITINATION; UNFOLDED PROTEIN RESPONSE;

EID: 85032009771     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2017.00259     Document Type: Review

References (173)

1. Anchisi, L., Dessi, S., Pani, A., and Mandas, A. (2013). Cholesterol homeostasis: a key to prevent or slow down neurodegeneration. Front. Physiol. 3:486. doi: 10.3389/fphys.2012.00486
2. Ballar, P., Ors, A. U., Yang, H., and Fang, S. (2010). Differential regulation of CFTRDeltaF508 degradation by ubiquitin ligases gp78 and Hrd1. Int. J. Biochem. Cell Biol. 42, 167–173. doi: 10.1016/j.biocel.2009.10.005
3. Ballar, P., Shen, Y., Yang, H., and Fang, S. (2006). The role of a novel p97/valosincontaining protein-interacting motif of gp78 in endoplasmic reticulumassociated degradation. J. Biol. Chem. 281, 35359–35368. doi: 10.1074/jbc.M603355200
4. Ballar, P., Zhong, Y., Nagahama, M., Tagaya, M., Shen, Y., and Fang, S. (2007). Identification of SVIP as an endogenous inhibitor of endoplasmic reticulumassociated degradation. J. Biol. Chem. 282, 33908–33914. doi: 10.1074/jbc.M704446200
5. Benlimame, N., Le, P. U., and Nabi, I. R. (1998). Localization of autocrine motility factor receptor to caveolae and clathrin-independent internalization of its ligand to smooth endoplasmic reticulum. Mol. Biol. Cell 9, 1773–1786. doi: 10.1091/mbc.9.7.1773
6. Benlimame, N., Simard, D., and Nabi, I. R. (1995). Autocrine motility factor receptor is a marker for a distinct membranous tubular organelle. J. Cell Biol. 129, 459–471. doi: 10.1083/jcb.129.2.459
7. Braakman, I., and Bulleid, N. J. (2011). Protein folding and modification in the mammalian endoplasmic reticulum. Annu. Rev. Biochem. 80, 71–99. doi: 10.1146/annurev-biochem-062209-093836
8. Brandman, O., and Hegde, R. S. (2016). Ribosome-associated protein quality control. Nat. Struct. Mol. Biol. 23, 7–15. doi: 10.1038/nsmb.3147
9. Buchberger, A., Bukau, B., and Sommer, T. (2010). Protein quality control in the cytosol and the endoplasmic reticulum: brothers in arms. Mol. Cell 40, 238–252. doi: 10.1016/j.molcel.2010.10.001
10. Cao, J., Wang, J., Qi, W., Miao, H. H., Wang, J., Ge, L., et al. (2007). Ufd1 is a cofactor of gp78 and plays a key role in cholesterol metabolism by regulating the stability of HMG-CoA reductase. Cell Metab. 6, 115–128. doi: 10.1016/j.cmet.2007.07.002
11. Carpenter, J. E., and Grose, C. (2014). Varicella-zoster virus glycoprotein expression differentially induces the unfolded protein response in infected cells. Front. Microbiol. 5:322. doi: 10.3389/fmicb.2014.00322
12. Chang, Y. W., Tseng, C. F., Wang, M. Y., Chang, W. C., Lee, C. C., Chen, L. T., et al. (2015). Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer. Oncogene 35, 1517–1528. doi: 10.1038/onc.2015.214
13. Chen, Z., Ballar, P., Fu, Y., Luo, J., Du, S., and Fang, S. (2014). The E3 ubiquitin ligase gp78 protects against ER stress in zebrafish liver. J. Genet. Genomics 41, 357–368. doi: 10.1016/j.jgg.2014.05.005
14. Chen, Z., Du, S., and Fang, S. (2012). Gp78: a multifaceted ubiquitin ligase that integrates a unique protein degradation pathway from the endoplasmic reticulum. Curr. Protein Pept. Sci. 13, 414–424. doi: 10.2174/138920312802430590
15. Chen, B., Mariano, J., Tsai, Y. C., Chan, A. H., Cohen, M., and Weissman, A. M. (2006). The activity of a human endoplasmic reticulum-associated degradation E3, gp78, requires its Cue domain, RING finger and an E2-binding site. Proc. Natl. Acad. Sci. U S A 103, 341–346. doi: 10.1073/pnas.0506618103
16. Chen, B., Retzlaff, M., Roos, T., and Frydman, J. (2011). Cellular strategies of protein quality control. Cold Spring Harb. Perspect. Biol. 3:a004374. doi: 10.1101/cshperspect.a004374
17. Chhangani, D., Chinchwadkar, S., and Mishra, A. (2014). Autophagy coupling interplay: can improve cellular repair and aging? Mol. Neurobiol. 49, 1270–1281. doi: 10.1007/s12035-013-8599-z
18. Chhangani, D., Joshi, A. P., and Mishra, A. (2012). E3 ubiquitin ligases in protein quality control mechanism. Mol. Neurobiol. 45, 571–585. doi: 10.1007/s12035-012-8273-x
19. Chhangani, D., and Mishra, A. (2013). Protein quality control system in neurodegeneration: a healing company hard to beat but failure is fatal. Mol. Neurobiol. 48, 141–156. doi: 10.1007/s12035-013-8411-0
20. Chiu, C. G., St-Pierre, P., Nabi, I. R., and Wiseman, S. M. (2008). Autocrine motility factor receptor: a clinical review. Expert Rev. Anticancer Ther. 8, 207–217. doi: 10.1586/14737140.8.2.207
21. Choi, K., Kim, H., Kang, H., Lee, S. Y., Lee, S. J., Back, S. H., et al. (2014). Regulation of diacylglycerol acyltransferase 2 protein stability by gp78-associated endoplasmic-reticulum-associated degradation. FEBS J. 281, 3048–3060. doi: 10.1111/febs.12841
22. Choudhury, Y., Tay, F. C., Lam, D. H., Sandanaraj, E., Tang, C., Ang, B.-T., et al. (2012). Attenuated adenosine-to-inosine editing of microRNA-376a_ promotes invasiveness of glioblastoma cells. J. Clin. Invest. 122, 4059–4076. doi: 10.1172/JCI62925
23. Christianson, J. C., and Ye, Y. (2014). Cleaning up in the endoplasmic reticulum: ubiquitin in charge. Nat. Struct. Mol. Biol. 21, 325–335. doi: 10.1038/nsmb.2793
24. Das, R., Mariano, J., Tsai, Y. C., Kalathur, R. C., Kostova, Z., Li, J., et al. (2009). Allosteric activation of E2-RING finger-mediated ubiquitylation by a structurally defined specific E2-binding region of gp78. Mol. Cell 34, 674–685. doi: 10.1016/j.molcel.2009.05.010
25. Debose-Boyd, R. A. (2008). Feedback regulation of cholesterol synthesis: sterolaccelerated ubiquitination and degradation of HMG CoA reductase. Cell Res. 18, 609–621. doi: 10.1038/cr.2008.61
26. Ellis, R. J. (2001). Macromolecular crowding: obvious but underappreciated. Trends Biochem. Sci. 26, 597–604. doi: 10.1016/s0968-0004(01)01938-7
27. Endo, K., Shirai, A., Furukawa, M., and Yoshizaki, T. (2006). Prognostic value of cell motility activation factors in patients with tongue squamous cell carcinoma. Hum. Pathol. 37, 1111–1116. doi: 10.1016/j.humpath.2006.03.020
28. Fairbank, M., St-Pierre, P., and Nabi, I. R. (2009). The complex biology of autocrine motility factor/phosphoglucose isomerase (AMF/PGI) and its receptor, the gp78/AMFR E3 ubiquitin ligase. Mol. Biosyst. 5, 793–801. doi: 10.1039/b820820b
29. Fang, S., Ferrone, M., Yang, C., Jensen, J. P., Tiwari, S., and Weissman, A. M. (2001). The tumor autocrine motility factor receptor, gp78, is a ubiquitin protein ligase implicated in degradation from the endoplasmic reticulum. Proc. Natl. Acad. Sci. U S A 98, 14422–14427. doi: 10.1073/pnas.251401598
30. Fang, S., Lorick, K. L., Jensen, J. P., and Weissman, A. M. (2003). RING finger ubiquitin protein ligases: implications for tumorigenesis, metastasis and for molecular targets in cancer. Semin Cancer Biol. 13, 5–14. doi: 10.1016/s1044-579x(02)00095-0
31. Fisher, E. A., Lapierre, L. R., Junkins, R. D., and McLeod, R. S. (2008). The AAA-ATPase p97 facilitates degradation of apolipoprotein B by the ubiquitinproteasome pathway. J. Lipid Res. 49, 2149–2160. doi: 10.1194/jlr.M800108-JLR200
32. Fu, M., Li, L., Albrecht, T., Johnson, J. D., Kojic, L. D., and Nabi, I. R. (2011). Autocrine motility factor/phosphoglucose isomerase regulates ER stress and cell death through control of ER calcium release. Cell Death Differ. 18, 1057–1070. doi: 10.1038/cdd.2010.181
33. Fu, M., St-Pierre, P., Shankar, J., Wang, P. T., Joshi, B., and Nabi, I. R. (2013). Regulation of mitophagy by the Gp78 E3 ubiquitin ligase. Mol. Biol. Cell 24, 1153–1162. doi: 10.1091/mbc.E12-08-0607
34. Funasaka, T., Haga, A., Raz, A., and Nagase, H. (2001). Tumor autocrine motility factor is an angiogenic factor hat stimulates endothelial cell motility. Biochem. Biophys. Res. Commun. 284, 1116–1125. doi: 10.1006/bbrc.2001.4912
35. Funasaka, T., Haga, A., Raz, A., and Nagase, H. (2002). Autocrine motility factor secreted by tumor cells upregulates vascular endothelial growth factor receptor (Flt-1) expression in endothelial cells. Int. J. Cancer 101, 217–223. doi: 10.1002/ijc.10617
36. Funasaka, T., Hu, H., Yanagawa, T., Hogan, V., and Raz, A. (2007). Downregulation of phosphoglucose isomerase/autocrine motility factor results in mesenchymal-to-epithelial transition of human lung fibrosarcoma cells. Cancer Res. 67, 4236–4243. doi: 10.1158/0008-5472.can-06-3935
37. Gestwicki, J. E., and Garza, D. (2012). Protein quality control in neurodegenerative disease. Prog. Mol. Biol. Transl. Sci. 107, 327–353. doi: 10.1016/B978-0-12-385883-2.00003-5
38. Goetz, J. G., Genty, H., St-Pierre, P., Dang, T., Joshi, B., Sauvé, R., et al. (2007). Reversible interactions between smooth domains of the endoplasmic reticulum and mitochondria are regulated by physiological cytosolic Ca2C levels. J. Cell Sci. 120, 3553–3564. doi: 10.1242/jcs.03486
39. Guenther, R., Krenn, V., Morawietz, L., Dankof, A., Melcher, I., Schaser, K. D., et al. (2005). Giant cell tumors of the bone: molecular profiling and expression analysis of Ephrin A1 receptor, Claudin 7, CD52, FGFR3 and AMFR. Pathol. Res. Pract. 201, 649–663. doi: 10.1016/j.prp.2005.07.005
40. Haga, A., Tanaka, N., Funasaka, T., Hashimoto, K., Nakamura, K. T., Watanabe, H., et al. (2006). The autocrine motility factor (AMF) and AMF-receptor combination needs sugar chain recognition ability and interaction using the C-terminal region of AMF. J. Mol. Biol. 358, 741–753. doi: 10.1016/j.jmb.2006.02.046
41. Hara, T., Hashimoto, Y., Akuzawa, T., Hirai, R., Kobayashi, H., and Sato, K. (2014). Rer1 and calnexin regulate endoplasmic reticulum retention of a peripheral myelin protein 22 mutant that causes type 1A Charcot-Marie-Tooth disease. Sci. Rep. 4:6992. doi: 10.1038/srep06992
42. Hartl, F. U. (2017). Protein misfolding diseases. Annu. Rev. Biochem. 86, 21–26. doi: 10.1146/annurev-biochem-061516-044518
43. Hartl, F. U., Bracher, A., and Hayer-Hartl, M. (2011). Molecular chaperones in protein folding and proteostasis. Nature 475, 324–332. doi: 10.1038/nature10317
44. Hebert, D. N., and Molinari, M. (2007). In and out of the ER: protein folding, quality control, degradation, and related human diseases. Physiol. Rev. 87, 1377–1408. doi: 10.1152/physrev.00050.2006
45. Hendrix, M. J., Wood, W. R., Seftor, E. A., Lotan, D., Nakajima, M., Misiorowski, R. L., et al. (1990). Retinoic acid inhibition of human melanoma cell invasion through a reconstituted basement membrane and its relation to decreases in the expression of proteolytic enzymes and motility factor receptor. Cancer Res. 50, 4121–4130.
46. Hershko, A., and Ciechanover, A. (1992). The ubiquitin system for protein degradation. Ann. Rev. Biochem. 61, 761–807. doi: 10.1146/annurev.bi.61.070192.003553
47. Hipp, M. S., Park, S.-H., and Hartl, F. U. (2014). Proteostasis impairment in protein-misfolding and-aggregation diseases. Trends Cell Biol. 24, 506–514. doi: 10.1016/j.tcb.2014.05.003
48. Hirono, Y., Fushida, S., Yonemura, Y., Yamamoto, H., Watanabe, H., and Raz, A. (1996). Expression of autocrine motility factor receptor correlates with disease progression in human gastric cancer. Br. J. Cancer 74, 2003–2007. doi: 10.1038/bjc.1996.667
49. Hishizawa, M., Imada, K., Sakai, T., Nishikori, M., Arima, N., Tsudo, M., et al. (2006). Antibody responses associated with the graft-versus-leukemia effect in adult T-cell leukemia. Int. J. Hematol. 83, 351–355. doi: 10.1532/ijh97.05173
50. Iiizumi, M., Liu, W., Pai, S. K., Furuta, E., and Watabe, K. (2008). Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. Biochim. Biophys. Acta 1786, 87–104. doi: 10.1016/j.bbcan.2008.07.002
51. Ishikawa, H., Ma, Z., and Barber, G. N. (2009). STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461, 788–792. doi: 10.1038/nature08476
52. Jacobs, J. L., Zhu, J., Sarkar, S. N., and Coyne, C. B. (2014). Regulation of mitochondrial antiviral signaling (MAVS) expression and signaling by the mitochondria-associated endoplasmic reticulum membrane (MAM) protein Gp78. J. Biol. Chem. 289, 1604–1616. doi: 10.1074/jbc.M113.520254
53. Jiang, W. G., Raz, A., Douglas-Jones, A., and Mansel, R. E. (2006). Expression of autocrine motility factor (AMF) and its receptor, AMFR, in human breast cancer. J. Histochem. Cytochem. 54, 231–241. doi: 10.1369/jhc.5a6785.2005
54. Joshi, V., Amanullah, A., Upadhyay, A., Mishra, R., Kumar, A., and Mishra, A. (2016). A decade of boon or burden: what has the CHIP ever done for cellular protein quality control mechanism implicated in neurodegeneration and aging? Front. Mol. Neurosci. 9:93. doi: 10.3389/fnmol.2016.00093
55. Joshi, B., Li, L., and Nabi, I. R. (2010). A role for KAI1 in promotion of cell proliferation and mammary gland hyperplasia by the gp78 ubiquitin ligase. J. Biol. Chem. 285, 8830–8839. doi: 10.1074/jbc.M109.074344
56. Kara, M., Ohta, Y., Tanaka, Y., Oda, M., and Watanabe, Y. (2001). Autocrine motility factor receptor expression in patients with stage I non-small cell lung cancer. Ann. Thorac Surg. 71, 944–948. doi: 10.1016/s0003-4975(00)02135-4
57. Kawanishi, K., Doki, Y., Shiozaki, H., Yano, M., Inoue, M., Fukuchi, N., et al. (2000). Correlation between loss of E-cadherin expression and overexpression of autocrine motility factor receptor in association with progression of human gastric cancers. Am. J. Clin. Pathol. 113, 266–274. doi: 10.1309/jh4q-25q5-0trv-w99u
58. Kaynak, K., Kara, M., Oz, B., Akgoz, B., Sar, M., and Raz, A. (2005). Autocrine motility factor receptor expression implies an unfavourable prognosis in resected stage I pulmonary adenocarcinomas. Acta Chir. Belg. 105, 378–382. doi: 10.1080/00015458.2005.11679740
59. Kim, S. M., Acharya, P., Engel, J. C., and Correia, M. A. (2010). Liver cytochrome P450 3A ubiquitination in vivo by gp78/autocrine motility factor receptor and C terminus of Hsp70-interacting protein (CHIP) E3 ubiquitin ligases: physiological and pharmacological relevance. J. Biol. Chem. 285, 35866–35877. doi: 10.1074/jbc.M110.167189
60. Kojic, L. D., Wiseman, S. M., Ghaidi, F., Joshi, B., Nedev, H., Saragovi, H. U., et al. (2008). Raft-dependent endocytosis of autocrine motility factor/phosphoglucose isomerase: a potential drug delivery route for tumor cells. PLoS One 3:e3597. doi: 10.1371/journal.pone.0003597
61. Kopito, R. R. (1997). ER quality control: the cytoplasmic connection. Cell 88, 427–430. doi: 10.1016/s0092-8674(00)81881-4
62. Korman, H. J., Peabody, J. O., Cerny, J. C., Farah, R. N., Yao, J., and Raz, A. (1996). Autocrine motility factor receptor as a possible urine marker for transitional cell carcinoma of the bladder. J. Urol. 155, 347–349. doi: 10.1097/00005392-199601000-00137
63. Kuang, E., Qi, J., and Ronai, Z. E. (2013). Emerging roles of E3 ubiquitin ligases in autophagy. Trends Biochem. Sci. 38, 453–460. doi: 10.1016/j.tibs.2013.06.008
64. Le, P. U., Benlimame, N., Lagana, A., Raz, A., and Nabi, I. R. (2000). Clathrinmediated endocytosis and recycling of autocrine motility factor receptor to fibronectin fibrils is a limiting factor for NIH-3T3 cell motility. J. Cell Sci. 113, 3227–3240. doi: 10.1007/978-3-0348-7494-6_11
65. Leclerc, N., Vallée, A., and Nabi, I. R. (2000). Expression of the AMF/neuroleukin receptor in developing and adult brain cerebellum. J. Neurosci. Res. 60, 602–612. doi: 10.1002/(sici)1097-4547(20000601)60:5<602::aid-jnr5>3.3.co;2-6
66. Lemasters, J. J. (2005). Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. Rejuvenation Res. 8, 3–5. doi: 10.1089/rej.2005.8.3
67. Li, L., Gao, G., Shankar, J., Joshi, B., Foster, L. J., and Nabi, I. R. (2015). p38 MAP kinase-dependent phosphorylation of the Gp78 E3 ubiquitin ligase controls ER-mitochondria association and mitochondria motility. Mol. Biol. Cell 26, 3828–3840. doi: 10.1091/mbc.E15-02-0120
68. Li, W., Tu, D., Li, L., Wollert, T., Ghirlando, R., Brunger, A. T., et al. (2009). Mechanistic insights into active site-associated polyubiquitination by the ubiquitin-conjugating enzyme Ube2g2. Proc. Natl. Acad. Sci. U S A 106, 3722–3727. doi: 10.1073/pnas.0808564106
69. Liang, J. S., Kim, T., Fang, S., Yamaguchi, J., Weissman, A. M., Fisher, E. A., et al. (2003). Overexpression of the tumor autocrine motility factor receptor Gp78, a ubiquitin protein ligase, results in increased ubiquitinylation and decreased secretion of apolipoprotein B100 in HepG2 cells. J. Biol. Chem. 278, 23984–23988. doi: 10.1074/jbc.M302683200
70. Liotta, L. A., Mandler, R., Murano, G., Katz, D. A., Gordon, R. K., Chiang, P. K., et al. (1986). Tumor cell autocrine motility factor. Proc. Natl. Acad. Sci. U S A 83, 3302–3306. doi: 10.1073/pnas.83.10.3302
71. Liu, T. F., Tang, J. J., Li, P. S., Shen, Y., Li, J. G., Miao, H. H., et al. (2012). Ablation of gp78 in liver improves hyperlipidemia and insulin resistance by inhibiting SREBP to decrease lipid biosynthesis. Cell Metab. 16, 213–225. doi: 10.1016/j.cmet.2012.06.014
72. Lotan, R., Amos, B., Watanabe, H., and Raz, A. (1992). Suppression of melanoma cell motility factor receptor expression by retinoic acid. Cancer Res. 52, 4878–4884.
73. Luo, Y., Long, J. M., Lu, C., Chan, S. L., Spangler, E. L., Mascarucci, P., et al. (2002). A link between maze learning and hippocampal expression of neuroleukin and its receptor gp78. J. Neurochem. 80, 354–361. doi: 10.1046/j.0022-3042.2001.00707.x
74. Madore, H. P., and England, J. M. (1977). Rabies virus protein synthesis in infected BHK-21 cells. J. Virol. 22, 102–112.
75. Maruyama, K., Watanabe, H., Shiozaki, H., Takayama, T., Gofuku, J., Yano, H., et al. (1995). Expression of autocrine motility factor receptor in human esophageal squamous cell carcinoma. Int. J. Cancer 64, 316–321. doi: 10.1002/ijc.2910640506
76. McClellan, A. J., Tam, S., Kaganovich, D., and Frydman, J. (2005). Protein quality control: chaperones culling corrupt conformations. Nat. Cell Biol. 7, 736–741. doi: 10.1038/ncb0805-736
77. Mehnert, M., Sommer, T., and Jarosch, E. (2010). ERAD ubiquitin ligases: multifunctional tools for protein quality control and waste disposal in the endoplasmic reticulum. Bioessays 32, 905–913. doi: 10.1002/bies.201000046
78. Metzger, M. B., Hristova, V. A., and Weissman, A. M. (2012). HECT and RING finger families of E3 ubiquitin ligases at a glance. J. Cell Sci. 125, 531–537. doi: 10.1242/jcs.091777
79. Metzger, M. B., Pruneda, J. N., Klevit, R. E., and Weissman, A. M. (2014). RINGtype E3 ligases: master manipulators of E2 ubiquitin-conjugating enzymes and ubiquitination. Biochim. Biophys. Acta 1843, 47–60. doi: 10.1016/j.bbamcr.2013.05.026
80. Minton, A. P. (2000). Implications of macromolecular crowding for protein assembly. Curr. Opin. Struct. Biol. 10, 34–39. doi: 10.1016/s0959-440x(99)00045-7
81. Miranda, E., Römisch, K., and Lomas, D. A. (2004). Mutants of neuroserpin that cause dementia accumulate as polymers within the endoplasmic reticulum. J. Biol. Chem. 279, 28283–28291. doi: 10.1074/jbc.M313166200
82. Miyoshi, D., and Sugimoto, N. (2008). Molecular crowding effects on structure and stability of DNA. Biochimie 90, 1040–1051. doi: 10.1016/j.biochi.2008.02.009
83. Morito, D., Hirao, K., Oda, Y., Hosokawa, N., Tokunaga, F., Cyr, D. M., et al. (2008). Gp78 cooperates with RMA1 in endoplasmic reticulumassociated degradation of CFTRDeltaF508. Mol. Biol. Cell 19, 1328–1336. doi: 10.1091/mbc.E07-06-0601
84. Mukherjee, R., and Chakrabarti, O. (2016). Ubiquitin-mediated regulation of the E3 ligase GP78 by MGRN1 in trans affects mitochondrial homeostasis. J. Cell Sci. 129, 757–773. doi: 10.1242/jcs.176537
85. Nabi, I. R., Guay, G., and Simard, D. (1997). AMF-R tubules concentrate in a pericentriolar microtubule domain after MSV transformation of epithelial MDCK cells. J. Histochem. Cytochem. 45, 1351–1363. doi: 10.1177/002215549704501004
86. Nabi, I. R., and Raz, A. (1987). Cell shape modulation alters glycosylation of a metastatic melanoma cell-surface antigen. Int. J. Cancer 40, 396–402. doi: 10.1002/ijc.2910400319
87. Nabi, I. R., Watanabe, H., and Raz, A. (1990). Identification of B16–F1 melanoma autocrine motility-like factor receptor. Cancer Res. 50, 409–414.
88. Nabi, I. R., Watanabe, H., and Raz, A. (1992). Autocrine motility factor and its receptor: role in cell locomotion and metastasis. Cancer Metastasis Rev. 11, 5–20. doi: 10.1007/bf00047599
89. Nabi, I. R., Watanabe, H., Silletti, S., and Raz, A. (1991). Tumor cell autocrine motility factor receptor. EXS 59, 163–177. doi: 10.1007/978-3-0348-7494-6_11
90. Nagai, Y., Ishikawa, O., Miyachi, Y., and Watanabe, H. (1996). Expression of autocrine motility factor receptor in cutaneous malignant melanoma. Dermatology 192, 8–11. doi: 10.1159/000246304
91. Nakamori, S., Watanabe, H., Kameyama, M., Imaoka, S., Furukawa, H., Ishikawa, O., et al. (1994). Expression of autocrine motility factor receptor in colorectal cancer as a predictor for disease recurrence. Cancer 74, 1855–1862. doi: 10.1002/1097-0142(19941001)74:7<1855::AIDCNCR2820740705>3.0.CO;2-1
92. Nakayama, K. I., and Nakayama, K. (2006). Ubiquitin ligases: cell-cycle control and cancer. Nat. Rev. Cancer 6, 369–381. doi: 10.1038/nrc1881
93. Narendra, D., Tanaka, A., Suen, D. F., and Youle, R. J. (2008). Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 183, 795–803. doi: 10.1083/jcb.200809125
94. Niinaka, Y., Haga, A., Negishi, A., Yoshimasu, H., Raz, A., and Amagasa, T. (2002). Regulation of cell motility via high and low affinity autocrine motility factor (AMF) receptor in human oral squamous carcinoma cells. Oral Oncol. 38, 49–55. doi: 10.1016/s1368-8375(01)00022-7
95. Niinaka, Y., Oida, S., Ishisaki, A., Takeda, K., Iimura, T., Maruoka, Y., et al. (1996). Autocrine motility factor and its receptor expressions in human oral squamous cell carcinoma (SCC) cells. Int. J. Oncol. 9, 433–438. doi: 10.3892/ijo.9.3.433
96. Ohta, Y., Minato, H., Tanaka, Y., Go, T., Oda, M., and Watanabe, Y. (2000a). Autocrine motility factor receptor expression associates with tumor progression in thymoma. Int. J. Oncol. 17, 259–264. doi: 10.3892/ijo.17.2.259
97. Ohta, Y., Tanaka, Y., Hara, T., Oda, M., Watanabe, S., Shimizu, J., et al. (2000b). Clinicopathological and biological assessment of lung cancers with pleural dissemination. Ann. Thorac Surg. 69, 1025–1029. doi: 10.1016/s0003-4975(99)01579-9
98. Onishi, Y., Tsukada, K., Yokota, J., and Raz, A. (2003). Overexpression of autocrine motility factor receptor (AMFR) in NIH3T3 fibroblasts induces cell transformation. Clin. Exp. Metastasis 20, 51–58. doi: 10.1023/A:1022594503657
99. Otto, T., Bex, A., Schmidt, U., Raz, A., and Rübben, H. (1997). Improved prognosis assessment for patients with bladder carcinoma. Am. J. Pathol. 150, 1919–1923.
100. Otto, T., Birchmeier, W., Schmidt, U., Hinke, A., Schipper, J., Rübben, H., et al. (1994). Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas. Cancer Res. 54, 3120–3123.
101. Pabarcus, M. K., Hoe, N., Sadeghi, S., Patterson, C., Wiertz, E., and Correia, M. A. (2009). CYP3A4 ubiquitination by gp78 (the tumor autocrine motility factor receptor, AMFR) and CHIP E3 ligases. Arch. Biochem. Biophys. 483, 66–74. doi: 10.1016/j.abb.2008.12.001
102. Peer, C. J., Sissung, T. M., and Figg, W. D. (2011). CHIP and gp78-mediated ubiquitination of CYP3A4: implications for the pharmacology of anticancer agents. Cancer Biol. Ther. 11, 549–551. doi: 10.4161/cbt.11.6.14834
103. Ponting, C. P. (2000). Proteins of the endoplasmic-reticulum-associated degradation pathway: domain detection and function prediction. Biochem. J. 351, 527–535. doi: 10.1042/0264-6021:3510527
104. Prusiner, S. B. (1991). Molecular biology of prion diseases. Science 252, 1515–1523. doi: 10.1126/science.1675487
105. Roa, B. B., Garcia, C. A., Suter, U., Kulpa, D. A., Wise, C. A., Mueller, J., et al. (1993). Charcot-marie-tooth disease type 1A—association with a spontaneous point mutation in the PMP22 gene. N. Engl. J. Med. 329, 96–101. doi: 10.1136/jmg.30.10.885-b
106. Romagnoli, A., Oliverio, S., Evangelisti, C., Iannicola, C., Ippolito, G., and Piacentini, M. (2003). Neuroleukin inhibition sensitises neuronal cells to caspase-dependent apoptosis. Biochem. Biophys. Res. Commun. 302, 448–453. doi: 10.1016/s0006-291x(03)00188-8
107. Saibil, H. (2013). Chaperone machines for protein folding, unfolding and disaggregation. Nat. Rev. Mol. Cell Biol. 14, 630–642. doi: 10.1038/nrm3658
108. Seirafi, M., Kozlov, G., and Gehring, K. (2015). Parkin structure and function. FEBS J. 282, 2076–2088. doi: 10.1111/febs.13249
109. Shang, Y., and Zhu, Z. (2013). gp78 is specifically expressed in human prostate cancer rather than normal prostate tissue. J. Mol. Histol. 44, 653–659. doi: 10.1007/s10735-013-9512-9
110. Shankar, J., Kojic, L. D., St-Pierre, P., Wang, P. T., Fu, M., Joshi, B., et al. (2013). Raft endocytosis of AMF regulates mitochondrial dynamics through Rac1 signaling and the Gp78 ubiquitin ligase. J. Cell Sci. 126, 3295–3304. doi: 10.1242/jcs.120162
111. Shao, J., Choe, V., Cheng, H., Tsai, Y. C., Weissman, A. M., Luo, S., et al. (2014). Ubiquitin ligase gp78 targets unglycosylated prion protein PrP for ubiquitylation and degradation. PLoS One 9:e92290. doi: 10.1371/journal.pone.0092290
112. Sharma, S. K., De los Rios, P., Christen, P., Lustig, A., and Goloubinoff, P. (2010). The kinetic parameters and energy cost of the Hsp70 chaperone as a polypeptide unfoldase. Nat. Chem. Biol. 6, 914–920. doi: 10.1038/nchembio.455
113. Sharon, N. (1984). Glycoproteins. Trends Biochem. Sci. 9, 198–202. doi: 10.1016/0968-0004(84)90139-7
114. Shen, Y., Ballar, P., Apostolou, A., Doong, H., and Fang, S. (2007). ER stress differentially regulates the stabilities of ERAD ubiquitin ligases and their substrates. Biochem. Biophys. Res. Commun. 352, 919–924. doi: 10.1016/j.bbrc.2006.11.121
115. Shen, Y., Ballar, P., and Fang, S. (2006). Ubiquitin ligase gp78 increases solubility and facilitates degradation of the Z variant of a-1-antitrypsin. Biochem. Biophys. Res. Commun. 349, 1285–1293. doi: 10.1016/j.bbrc.2006.08.173
116. Shimizu, K., Tani, M., Watanabe, H., Nagamachi, Y., Niinaka, Y., Shiroishi, T., et al. (1999). The autocrine motility factor receptor gene encodes a novel type of seven transmembrane protein1. FEBS Lett. 456, 295–300. doi: 10.1016/s0014-5793(99)00966-7
117. Shmueli, A., Tsai, Y. C., Yang, M., Braun, M. A., and Weissman, A. M. (2009). Targeting of gp78 for ubiquitin-mediated proteasomal degradation by Hrd1: cross-talk between E3s in the endoplasmic reticulum. Biochem. Biophys. Res. Commun. 390, 758–762. doi: 10.1016/j.bbrc.2009.10.045
118. Shu, H. B., and Wang, Y. Y. (2014). Adding to the STING. Immunity 41, 871–873. doi: 10.1016/j.immuni.2014.12.002
119. Shylaja, M., and Seshadri, H. S. (1989). Glycoproteins: an overview. Biochem. Edu. 17, 170–178. doi: 10.1016/0307-4412(89)90136-2
120. Silletti, S., and Raz, A. (1996). Regulation of autocrine motility factor receptor expression in tumor cell locomotion and metastasis. Curr. Top. Microbiol. Immunol. 213, 137–169. doi: 10.1007/978-3-642-61109-4_7
121. Silletti, S., Watanabe, H., Hogan, V., Nabi, I. R., and Raz, A. (1991). Purification of B16–F1 melanoma autocrine motility factor and its receptor. Cancer Res. 51, 3507–3511.
122. Silletti, S., Yao, J. P., Pienta, K. J., and Raz, A. (1995). Loss of cell-contact regulation and altered responses to autocrine motility factor correlate with increased malignancy in prostate cancer cells. Int. J. Cancer 63, 100–105. doi: 10.1002/ijc.2910630118
123. Silletti, S., Yao, J., Sanford, J., Mohammed, A., Otto, T., Wolman, S., et al. (1993). Autocrine motility factor-receptor in human bladder-carcinoma - geneexpression, loss of cell-contact regulation and chromosomal mapping. Int. J. Oncol. 3, 801–807. doi: 10.3892/ijo.3.5.801
124. Simard, D., and Nabi, I. R. (1996). Inverse relation of autocrine motility factor receptor and E-cadherin expression following MDCK epithelial cell transformation. Biochem. Biophys. Res. Commun. 219, 122–127. doi: 10.1006/bbrc.1996.0192
125. Song, B. L., Sever, N., and Debose-Boyd, R. A. (2005). Gp78, a membraneanchored ubiquitin ligase, associates with Insig-1 and couples sterol-regulated ubiquitination to degradation of HMG CoA reductase. Mol. Cell 19, 829–840. doi: 10.1016/j.molcel.2005.08.009
126. Song, M., Yin, Y., Zhang, J., Zhang, B., Bian, Z., Quan, C., et al. (2014). MiR–139–5p inhibits migration and invasion of colorectal cancer by downregulating AMFR and NOTCH1. Protein Cell 5, 851–861. doi: 10.1007/s13238-014-0093-5
127. Soto, C. (2003). Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 4, 49–60. doi: 10.1038/nrn1007
128. Soto, C., and Estrada, L. D. (2008). Protein misfolding and neurodegeneration. Arch. Neurol. 65, 184–189. doi: 10.1001/archneurol.2007.56
129. Spiro, R. G. (1970). Glycoproteins. Annu. Rev. Biochem. 39, 599–638. doi: 10.1146/annurev.bi.39.070170.003123
130. St-Pierre, P., Dang, T., Joshi, B., and Nabi, I. R. (2012). Peripheral endoplasmic reticulum localization of the Gp78 ubiquitin ligase activity. J. Cell Sci. 125, 1727–1737. doi: 10.1242/jcs.096396
131. Takanami, I., and Takeuchi, K. (2003). Autocrine motility factor-receptor gene expression in lung cancer. Jpn. J. Thorac. Cardiovasc. Surg. 51, 368–373. doi: 10.1007/BF02719469
132. Takanami, I., Takeuchi, K., Watanabe, H., Yanagawa, T., and Takagishi, K. (2002). Autocrine motility factor receptor gene expression and cell motility in lung cancer cell lines. Oncol. Rep. 9, 125–128. doi: 10.3892/or.9.1.125
133. Takanami, I., Takeuchi, K., Watanabe, H., Yanagawa, T., Takagishi, K., and Raz, A. (2001). Significance of autocrine motility factor receptor gene expression as a prognostic factor in non-small-cell lung cancer. Int. J. Cancer 95, 384–387. doi: 10.1002/1097-0215(20011120)95:6<384::aid-ijc1068>3.0.co;2-d
134. Taniguchi, K., Yonemura, Y., Nojima, N., Hirono, Y., Fushida, S., Fujimura, T., et al. (1998). The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor and urokinase-type plasminogen activator receptor. Cancer 82, 2112–2122. doi: 10.1002/(sici)1097-0142(19980601)82:11<2112::aidcncr5>3.0.co;2-x
135. Taraboulos, A., Rogers, M., Borchelt, D. R., Mckinley, M. P., Scott, M., Serban, D., et al. (1990). Acquisition of protease resistance by prion proteins in scrapieinfected cells does not require asparagine-linked glycosylation. Proc. Natl. Acad. Sci. U S A 87, 8262–8266. doi: 10.1073/pnas.87.21.8262
136. Tian, K., Zhong, W., Zheng, X., Zhang, J., Liu, P., Zhang, W., et al. (2015). Neuroleukin/autocrine motility factor receptor pathway promotes proliferation of articular chondrocytes through activation of AKT and Smad2/3. Sci. Rep. 5:15101. doi: 10.1038/srep15101
137. Tímár, J., Rásó, E., Döme, B., Ladányi, A., Bánfalvi, T., Gilde, K., et al. (2002). Expression and function of the AMF receptor by human melanoma in experimental and clinical systems. Clin. Exp. Metastasis 19, 225–232. doi: 10.1023/A:1015595708241
138. Timar, J., Silletti, S., Bazaz, R., Raz, A., and Honn, K. V. (1993). Regulation of melanoma-cell motility by the lipoxygenase metabolite 12-(S)-HETE. Int. J. Cancer 55, 1003–1010. doi: 10.1002/ijc.2910550621
139. Tsai, Y. C., Leichner, G. S., Pearce, M. M., Wilson, G. L., Wojcikiewicz, R. J., Roitelman, J., et al. (2012). Differential regulation of HMG-CoA reductase and Insig-1 by enzymes of the ubiquitin-proteasome system. Mol. Biol. Cell 23, 4484–4494. doi: 10.1091/mbc.e12-08-0631
140. Tsai, Y. C., Mendoza, A., Mariano, J. M., Zhou, M., Kostova, Z., Chen, B., et al. (2007). The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation. Nat. Med. 13, 1504–1509. doi: 10.1038/nm1686
141. Tsai, B., Ye, Y., and Rapoport, T. A. (2002). Retro-translocation of proteins from the endoplasmic reticulum into the cytosol. Nat. Rev. Mol. Cell Biol. 3, 246–255. doi: 10.1038/nrm780
142. Tsutsumi, S., Gupta, S. K., Hogan, V., Collard, J. G., and Raz, A. (2002). Activation of small GTPase Rho is required for autocrine motility factor signaling. Cancer Res. 62, 4484–4490.
143. Upadhyay, A., Amanullah, A., Chhangani, D., Mishra, R., and Mishra, A. (2015). Selective multifaceted E3 ubiquitin ligases barricade extreme defense: potential therapeutic targets for neurodegeneration and ageing. Ageing res.rev. 24, 138–159. doi: 10.1016/j.arr.2015.07.009
144. Upadhyay, A., Joshi, V., Amanullah, A., Mishra, R., Arora, N., Prasad, A., et al. (2017). E3 ubiquitin ligases neurobiological mechanisms: development to degeneration. Front. Mol. Neurosci. 10:151. doi: 10.3389/fnmol.2017.00151
145. Vij, N., Fang, S., and Zeitlin, P. L. (2006). Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications. J. Biol. Chem. 281, 17369–17378. doi: 10.1074/jbc.m600509200
146. Wang, H. J., Benlimame, N., and Nabi, I. (1997). The AMF-R tubule is a smooth ilimaquinone-sensitive subdomain of the endoplasmic reticulum. J. Cell Sci. 110, 3043–3053.
147. Wang, P. T., Garcin, P. O., Fu, M., Masoudi, M., St-Pierre, P., Pante, N., et al. (2015). Distinct mechanisms controlling rough and smooth endoplasmic reticulum contacts with mitochondria. J. Cell Sci. 128, 2759–2765. doi: 10.1242/jcs.171132
148. Wang, Y., Guan, S., Acharya, P., Liu, Y., Thirumaran, R. K., Brandman, R., et al. (2012). Multisite phosphorylation of human liver cytochrome P450 3A4 enhances Its gp78- and CHIP-mediated ubiquitination: a pivotal role of its Ser-478 residue in the gp78-catalyzed reaction. Mol. Cell. Proteomics 11:M111.010132. doi: 10.1074/mcp.m111.010132
149. Wang, H. J., Guay, G., Pogan, L., Sauvé, R., and Nabi, I. R. (2000). Calcium regulates the association between mitochondria and a smooth subdomain of the endoplasmic reticulum. J. Cell Biol. 150, 1489–1498. doi: 10.1083/jcb.150.6.1489
150. Wang, Y., Ha, S. W., Zhang, T., Kho, D. H., Raz, A., and Xie, Y. (2014). Polyubiquitylation of AMF requires cooperation between the gp78 and TRIM25 ubiquitin ligases. Oncotarget 5, 2044–2051. doi: 10.18632/oncotarget.1478
151. Wang, L., Hou, G., Xue, L., Li, J., Wei, P., and Xu, P. (2010). Autocrine motility factor receptor signaling pathway promotes cell invasion via activation of ROCK-2 in esophageal squamous cell cancer cells. Cancer Invest. 28, 993–1003. doi: 10.3109/07357907.2010.483503
152. Wang, Q., Jiao, F., Zhang, P., Yan, J., Zhang, Z., He, F., et al. (2017). CDK5-mediated phosphorylation-dependent ubiquitination and degradation of E3 ubiquitin ligases GP78 accelerates neuronal death in Parkinson’s disease. Mol. Neurobiol. doi: 10.1007/s12035-017-0579-2 [Epub ahead of print].
153. Wang, Y., Kim, S. M., Trnka, M. J., Liu, Y., Burlingame, A. L., and Correia, M. A. (2015a). Human liver cytochrome P450 3A4 ubiquitination: molecular recognition by UBC7-gp78 autocrine motility factor receptor and UbcH5a- CHIP-Hsc70-Hsp40 E2–E3 ubiquitin ligase complexes. J. Biol. Chem. 290, 3308–3332. doi: 10.1074/jbc.M114.611525
154. Wang, Y., Ma, L., Wang, C., Sheng, G., Feng, L., and Yin, C. (2015b). Autocrine motility factor receptor promotes the proliferation of human acute monocytic leukemia THP-1 cells. Int. J. Mol. Med. 36, 627–632. doi: 10.3892/ijmm.2015.2267
155. Wang, Q., Liu, X., Cui, Y., Tang, Y., Chen, W., Li, S., et al. (2014). The E3 ubiquitin ligase AMFR and INSIG1 bridge the activation of TBK1 kinase by modifying the adaptor STING. Immunity 41, 919–933. doi: 10.1016/j.immuni.2014.11.011
156. Wang, W., Yang, L. Y., Yang, Z. L., Peng, J. X., and Yang, J. Q. (2007). Elevated expression of autocrine motility factor receptor correlates with overexpression of RhoC and indicates poor prognosis in hepatocellular carcinoma. Dig. Dis. Sci. 52, 770–775. doi: 10.1007/s10620-006-9479-4
157. Watanabe, H., Carmi, P., Hogan, V., Raz, T., Silletti, S., Nabi, I. R., et al. (1991a). Purification of human tumor cell autocrine motility factor and molecular cloning of its receptor. J. Biol. Chem. 266, 13442–13448.
158. Watanabe, H., Nabi, I. R., and Raz, A. (1991b). The relationship between motility factor receptor internalization and the lung colonization capacity of murine melanoma cells. Cancer Res. 51, 2699–2705.
159. Watanabe, H., Kanbe, K., and Chigira, M. (1994). Differential purification of autocrine motility factor derived from a murine protein-free fibrosarcoma. Clin. Exp. Metastasis 12, 155–163. doi: 10.1007/bf01753982
160. Watanabe, H., Shinozaki, T., Raz, A., and Chigira, M. (1993). Expression of autocrine motility factor receptor in serum- and protein-independent fibrosarcoma cells: implications for autonomy in tumor-cell motility and metastasis. Int. J. Cancer 53, 689–695. doi: 10.1002/ijc.2910530427
161. Watanabe, H., Takehana, K., Date, M., Shinozaki, T., and Raz, A. (1996). Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide. Cancer Res. 56, 2960–2963.
162. White, D. A., Buell, A. K., Knowles, T. P. J., Welland, M. E., and Dobson, C. M. (2010). Protein aggregation in crowded environments. J. Am. Chem. Soc. 132, 5170–5175. doi: 10.1021/ja909997e
163. Yan, L., Liu, W., Zhang, H., Liu, C., Shang, Y., Ye, Y., et al. (2014). Ube2g2-gp78- mediated HERP polyubiquitylation is involved in ER stress recovery. J. Cell Sci. 127, 1417–1427. doi: 10.1242/jcs.135293
164. Yanagawa, T., Funasaka, T., Tsutsumi, S., Watanabe, H., and Raz, A. (2004). Novel roles of the autocrine motility factor/phosphoglucose isomerase in tumor malignancy. Endocr. Relat. Cancer 11, 749–759. doi: 10.1677/erc.1.00811
165. Yang, Y., Cheng, X. R., Zhang, G. R., Zhou, W. X., and Zhang, Y. X. (2012). Autocrine motility factor receptor is involved in the process of learning and memory in the central nervous system. Behav. Brain Res. 229, 412–418. doi: 10.1016/j.bbr.2012.01.043
166. Yang, H., Liu, C., Zhong, Y., Luo, S., Monteiro, M. J., and Fang, S. (2010). Huntingtin interacts with the cue domain of gp78 and inhibits gp78 binding to ubiquitin and p97/VCP. PLoS One 5:e8905. doi: 10.1371/journal.pone.0008905
167. Yelian, F. D., Liu, A., Todt, J. C., Lei, J., Qureshi, F., Jacques, S. M., et al. (1996). Expression and function of autocrine motility factor receptor in human choriocarcinoma. Gynecol. Oncol. 62, 159–165. doi: 10.1006/gyno.1996.0209
168. Ying, Z., Wang, H., Fan, H., and Wang, G. (2011). The endoplasmic reticulum (ER)-associated degradation system regulates aggregation and degradation of mutant neuroserpin. J. Biol. Chem. 286, 20835–20844. doi: 10.1074/jbc.m110.200808
169. Ying, Z., Wang, H., Fan, H., Zhu, X., Zhou, J., Fei, E., et al. (2009). Gp78, an ER associated E3, promotes SOD1 and ataxin-3 degradation. Hum. Mol. Genet. 18, 4268–4281. doi: 10.1093/hmg/ddp380
170. Youle, R. J., and Narendra, D. P. (2011). Mechanisms of mitophagy. Nat. Rev. Mol. Cell Biol. 12, 9–14. doi: 10.1038/nrm3028
171. Zhang, J., and Liu, Q. (2015). Cholesterol metabolism and homeostasis in the brain. Protein Cell 6, 254–264. doi: 10.1007/s13238-014-0131-3
172. Zhang, T., Kho, D. H., Wang, Y., Harazono, Y., Nakajima, K., Xie, Y., et al. (2015a). Gp78, an E3 ubiquitin ligase acts as a gatekeeper suppressing nonalcoholic steatohepatitis (NASH) and liver cancer. PLoS One 10:e0118448. doi: 10.1371/journal.pone.0118448
173. Zhang, T., Xu, Y., Liu, Y., and Ye, Y. (2015b). Gp78 functions downstream of Hrd1 to promote degradation of misfolded proteins of the endoplasmic reticulum. Mol. Biol. Cell 26, 4438–4450. doi: 10.1091/mbc.e15-06-0354